IN PARTNERSHIP


caused by customs inspections and temperature    VAT) that apply when importing comparator material from other markets must be assessed 


 It’s common for material sourced from a different market to have a different language and a different set of information than what is required in the market where patients are  required by local regulatory authorities needs  


 need to be translated into the local language? Should the label be translated into the market the material is sourced from or in the target market? If additional labelling activities are  •


  


• What is the time required to perform 


Even selecting a new or additional


packaging/labelling provider needs to be considered and can further impact timelines 


  on your clinical trial – even patients or patient


engagement can be impacted when you face a drug shortage situation without  Identifying potential risks when building a sourcing strategy will allow you to develop a   and keep patients engaged in the clinical trial. Thinking at an early stage about those


 with your selected sourcing partner early will enable you to build a robust and flexible 


CSI: the science-based leader in clinical   supported clients in similar situations and have the knowledge and experience to support you in identifying the risks and back-up options to be prepared for drug shortages and developing  


 route to improve the speed and agility of your study. We leverage our global network of over 95 manufacturers in emerging markets to source high-quality comparator drugs and  


For more information on how we identify    


Clinical Trial Supply Handbook | 21


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56